ArticlePatient preference and adherence2011
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.
Article in Patient preference and adherence, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.Clinical neuropharmacologyPooled it
- A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers.Drug design, development and therapy · 2019Trial
- Comparative safety of istradefylline in Parkinson's disease: A systematic review of randomized controlled trials and real-world studies.Clinical parkinsonism & related disorders · 2025Article
- Parkinson's Disease: Unravelling the Medicinal Perspectives and Recent Developments of Heterocyclic Monoamine Oxidase-B Inhibitors.CNS & neurological disorders drug targets · 2025Review
- Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.BMC neurology · 2023Article
- Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline.International journal of molecular sciences · 2023Article
- Identification of NewPharmaceuticals (Basel, Switzerland) · 2023Article
- KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Bilirubin: A Promising Therapy for Parkinson's Disease.International journal of molecular sciences · 2021Review
- Selegiline reduces daytime sleepiness in patients with Parkinson's disease.Brain and behavior · 2021Article
- Discovery ofJournal of enzyme inhibition and medicinal chemistry · 2020Article
- Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells.Neurotoxicity research · 2017Article
- Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic.Aging cell · 2016Review
- Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology.The Yale journal of biology and medicine · 2016Review
- Review
- Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.Frontiers in aging neuroscience · 2014Article
- Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action.CNS neuroscience & therapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease and the most treatable. Treatment of PD is symptomatic and generally focuses on the replacement or augmentation of levodopa. A number of options are available for treatment, both in monotherapy of early PD and to treat complications of advanced PD. This review focuses on rasagiline and selegiline, two medications that belong to a class of antiparkinsonian drugs called monoamine oxidase B (MAO-B) inhibitors. Topics covered in the review include mechanism of action, efficacy in early and advanced PD, effects on disability, the controversy regarding disease modification, safety, and patient preference for MAO-B inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.